# Evaluation of the Diagnostic Utility of INS316 in Patients With Interstitial Lung Diseases (01-701)

> **NCT01381666** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 22 (actual)

## Conditions studied

- Interstitial Lung Disease

## Interventions

- **DRUG:** INS316 solution for inhalation
- **DRUG:** hypertonic saline 3% sodium chloride solution

## Key facts

- **NCT ID:** NCT01381666
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-01
- **Primary completion:** 2004-04
- **Final completion:** 2004-04
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2015-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01381666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01381666, "Evaluation of the Diagnostic Utility of INS316 in Patients With Interstitial Lung Diseases (01-701)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01381666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*